Story

IonQ Surges on Quantum Computing Milestone; Six Flags Gains on Activist Sale Push

ENTHMSVIIDZHZH-TWJAKOHI
Sep 23, 20261 min read
IonQ Surges on Quantum Computing Milestone; Six Flags Gains on Activist Sale Push

Summary

IonQ shares jumped over 11% after the company announced a key technological advance in quantum error correction, while Six Flags Entertainment gained following a call from activist investor Jana Partners to explore a sale.

Text size
Background

Shares of IonQ surged in premarket trading Wednesday following a significant quantum computing announcement, while an activist push at Six Flags Entertainment also sent its stock higher, highlighting a market driven by company-specific catalysts.

U.S. stock futures were largely flat as investors digested a mix of corporate news ahead of the opening bell.

Tech and Activist Pressure Drive Movers

Quantum computing firm IonQ (IONQ) saw its shares rise 11.8% after announcing the successful development of what it called the industry’s first real-time quantum error-correction decoder. The company stated the technology addresses a critical challenge in creating fault-tolerant quantum computers, a key step toward building more powerful and reliable systems.

Meanwhile, Six Flags Entertainment (FUN) stock gained 5.7% after activist investor Jana Partners disclosed an economic stake of approximately 9% and urged the company's board to explore a potential sale. In a letter, Jana expressed dissatisfaction with the theme park operator's strategic direction and financial performance.

Healthcare Sector Sees Divergent Fortunes

Sample IUX Markets – In-articleAd

The healthcare and biotech sectors experienced significant volatility based on clinical and regulatory news.

  • TriSalus Life Sciences (TLSI) jumped 15.6% after the U.S. Food and Drug Administration granted 510(k) clearance for its TriNav Advance medical device, which is used in liver embolization procedures.
  • Immunovant (IMVT) shares fell 6% after the company reported that a proof-of-concept study of its drug candidate IMVT-1402 for cutaneous lupus erythematosus failed to meet its primary endpoint. Immunovant said it would discontinue development of the drug for that specific indication.
  • Maze Therapeutics (MAZE) rose 2.9% after CIBC initiated coverage on the stock with an "Outperform" rating.

Consumer Stocks in Focus

Restaurant operator Cracker Barrel (CBRL) surged 11% in premarket activity. The sharp gain followed the release of fiscal fourth-quarter 2026 results that reportedly came as a positive surprise to investors, surpassing modest analyst expectations.

Read next

More on Stocks
Back to latest news

LATEST